Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focusing on innovation and clinical needs to enhance its research and development efforts for its product pipeline in 2025 [1][2] Financial Performance - In 2024, the company achieved operating revenue of 4.453 billion yuan and a net profit attributable to shareholders of 1.191 billion yuan, representing year-on-year growth of 12.51% and 14.02% respectively [1] - In the first quarter of this year, the company reported operating revenue of 1.199 billion yuan and a net profit of 400 million yuan, with year-on-year increases of 9.7% and 7.09% respectively [1] Strategic Focus - The core competitive advantage of the company lies in its strategic layout and continuous innovation capabilities, which encompass product layout, research and development capacity, production capability, talent reserve, international development, and brand building [2] - The company has developed a diversified research and development system covering traditional Chinese medicine, antibody drugs, gene therapy, and small molecule drugs [2] Product Development - The company is advancing several innovative projects, including the "Shu Gan Jie Yu Capsule" for anxiety disorder in phase III clinical trials, and KH607 for depression in phase II clinical trials, as well as KH110 for Alzheimer's disease in phase III clinical trials [2] - KH815, a dual payload ADC drug, is the first of its kind to enter clinical trials globally, targeting advanced solid tumors with a dual mechanism of action [2] Future Direction - The company will continue to adhere to the business philosophy of "innovation as the core, quality as life" and will drive sustainable high-quality development through product innovation and industrial collaboration [3]

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | ☑其他 电话会议 | | 活动参与人员 | 参与单位名称及人员姓名： | | | 详见附件 | | | 上市公司接待人员姓名： | | | 董事、总裁 柯潇 | | | 董事、副总裁 殷劲群 | | | 副总裁、财务总监 钟建军 | | | 副总裁 徐燕华 | | | 董事会秘书 邓康 | | | 弘基生物总经理 郑强 | | 时间 2025 | 年 4 月 27 日 (周日) 下午 15:00-14:20 | | 地点 | 电话会议 | | 形式 口头 | | | 交流内容及具体 | 本次投资者交流会由公司总裁柯潇先生主持，并进行沟通 交流如下： | | | 1.问：请问康柏西普目前的国内市场格局以及后续的销售 | | | 增长空间如何？康柏西普各适应症的放量趋势？AAV疗法和康 | | 问答记录 | 柏的产品组合策略 ...

以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 超长续航模式。 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 资本寒冬，一家上市Bi o t e c h也没有挂掉。 1 8A生物科技七年之痒，7 0家公司（含摘B）仍然整整齐齐，一家没少，即使市值最小 的北海康成账上现金仅剩1亿元，但管理层认为2025年有足够的营运资金，即使诺辉健 康复牌暂时没有进展，但离生死大限还有5个月。 中国创新药处于少年时代，（在上市公司层面）有着足够的容错率和包容度，如同《百 年孤独》中初创的"马孔多"，这里全是年轻人，没有死亡，自然没有墓地。 然而，站在中国创新药1 0年节点之上，两大蜕变还是发生了。 今 非 昔 比 ， 《 创 新 药 供 给 侧 改 革 》 （ 2021 年 7 月 ） 指 出 的 内 卷 和 泡 沫 ， 如 今 都 不 再 严 重。 一是行业主要矛盾的蜕变，从同质化竞争的内部矛盾，转为中国生物科技快速崛起与美 国维持生物科技创新领域领导地位之间的外部矛盾。 二是创 ...

Core Insights - A total of 10 first-class innovative drugs have received clinical trial approval in China from April 14 to April 19, covering various types including small molecules, antibody-drug conjugates (ADC), gene therapy, and cell therapy, targeting conditions such as advanced solid tumors, type 1 diabetes, spinal cord injury, Duchenne muscular dystrophy (DMD), and paroxysmal nocturnal hemoglobinuria [1] Group 1: Company-Specific Developments - Hansoh Pharmaceutical's HS-10529, a KRAS G12D small molecule inhibitor, has been approved for clinical trials to treat advanced solid tumors with KRAS G12D mutations, showing good preclinical efficacy and safety [2] - Kanghong Pharmaceutical's KH815, a TROP2-targeted dual-payload ADC, has received clinical approval for treating advanced solid tumors, demonstrating potential to overcome drug resistance [3] - Innovent Biologics' IBI3020, a CEACAM5-targeted dual-payload ADC, has been approved for clinical trials aimed at treating unresectable, locally advanced, or metastatic solid tumors [4] - Xinneng Pharmaceutical's BBM-D101, an AAV gene therapy drug, has been approved for clinical trials to treat Duchenne muscular dystrophy (DMD), aiming for long-term efficacy with a single administration [5] - Zhixin Haosheng's E-islet 01, a universal allogeneic islet regeneration product, has received clinical approval for treating type 1 diabetes, utilizing advanced cell reprogramming techniques [6] - Shizhe Biotechnology's XS228, an iPSC-derived neural precursor cell injection, has been approved for clinical trials to treat subacute spinal cord injury (SCI) [7] - Baili Pharmaceutical's BL-M09D1, an ADC drug, has been approved for treating locally advanced or metastatic solid tumors, sharing technology with another ADC [8] - Renfu Innovation's HWS116, a biological product, has received clinical approval for treating advanced solid tumors, although specific mechanisms are not yet disclosed [9]